Switch theme
Sign up to access all valuation multiples
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
1990
32
LTM Revenue $16.2M
LTM EBITDA $2.3M
$12.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcoma has a last 12-month revenue (LTM) of $16.2M and a last 12-month EBITDA of $2.3M.
In the most recent fiscal year, Arcoma achieved revenue of $16.2M and an EBITDA of $2.3M.
Arcoma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcoma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $16.2M | XXX | $16.2M | XXX | XXX | XXX |
| Gross Profit | $6.5M | XXX | $6.5M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $2.3M | XXX | $2.3M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $1.4M | XXX | $1.4M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $1.1M | XXX | $1.2M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arcoma's stock price is SEK 10 (or $1).
Arcoma has current market cap of SEK 131M (or $13.5M), and EV of SEK 123M (or $12.7M).
See Arcoma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.7M | $13.5M | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arcoma has market cap of $13.5M and EV of $12.7M.
Arcoma's trades at 0.8x EV/Revenue multiple, and 5.6x EV/EBITDA.
Equity research analysts estimate Arcoma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcoma has a P/E ratio of 11.9x.
See valuation multiples for Arcoma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.5M | XXX | $13.5M | XXX | XXX | XXX |
| EV (current) | $12.7M | XXX | $12.7M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.6x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBIT | 8.8x | XXX | 9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.9x | XXX | 11.7x | XXX | XXX | XXX |
| EV/FCF | 10.2x | XXX | 10.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArcoma's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Arcoma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcoma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arcoma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcoma acquired XXX companies to date.
Last acquisition by Arcoma was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcoma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arcoma founded? | Arcoma was founded in 1990. |
| Where is Arcoma headquartered? | Arcoma is headquartered in Sweden. |
| How many employees does Arcoma have? | As of today, Arcoma has 32 employees. |
| Is Arcoma publicy listed? | Yes, Arcoma is a public company listed on STO. |
| What is the stock symbol of Arcoma? | Arcoma trades under ARCOMA ticker. |
| When did Arcoma go public? | Arcoma went public in 2014. |
| Who are competitors of Arcoma? | Similar companies to Arcoma include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Arcoma? | Arcoma's current market cap is $13.5M |
| What is the current revenue of Arcoma? | Arcoma's last 12 months revenue is $16.2M. |
| What is the current EV/Revenue multiple of Arcoma? | Current revenue multiple of Arcoma is 0.8x. |
| Is Arcoma profitable? | Yes, Arcoma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcoma? | Arcoma's last 12 months EBITDA is $2.3M. |
| What is Arcoma's EBITDA margin? | Arcoma's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Arcoma? | Current EBITDA multiple of Arcoma is 5.6x. |
| What is the current FCF of Arcoma? | Arcoma's last 12 months FCF is $1.2M. |
| What is Arcoma's FCF margin? | Arcoma's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Arcoma? | Current FCF multiple of Arcoma is 10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
